Label-free microscopic assessment of glioblastoma biopsy specimens prior to biobanking [corrected].
Glioblastoma is the most common primary brain tumor with a median 12- to 15-month patient survival. Improving patient survival involves better understanding the biological mechanisms of glioblastoma tumorigenesis and seeking targeted molecular therapies. Central to furthering these advances is the collection and storage of surgical biopsies (biobanking) for research. This paper addresses an imaging modality, confocal reflectance microscopy (CRM), for safely screening glioblastoma biopsy samples prior to biobanking to increase the quality of tissue provided for research and clinical trials. These data indicate that CRM can immediately identify cellularity of tissue biopsies from animal models of glioblastoma. When screening fresh human biopsy samples, CRM can differentiate a cellular glioblastoma biopsy from a necrotic biopsy without altering DNA, RNA, or protein expression of sampled tissue. These data illustrate CRM's potential for rapidly and safely screening clinical biopsy samples prior to biobanking, which demonstrates its potential as an effective screening technique that can improve the quality of tissue biobanked for patients with glioblastoma.
Neurosurgery Research Laboratory.
Joseph
J
Georges
Aqib
A
Zehri
Elizabeth
E
Carlson
Joshua
J
Nichols
Michael A
MA
Mooney
Nikolay L
NL
Martirosyan
Layla
L
Ghaffari
M Yashar S
MY
Kalani
Jennifer
J
Eschbacher
Burt
B
Feuerstein
Trent
T
Anderson
Mark C
MC
Preul
Kendall
K
Van Keuren-Jensen
Peter
P
Nakaji
D000818:Animals; D018070:Biological Specimen Banks / Q000592:standards; D001706:Biopsy; D001932:Brain Neoplasms / Q000473:pathology*; D045744:Cell Line, Tumor; D005909:Glioblastoma / Q000473:pathology*; D006801:Humans; D018613:Microscopy, Confocal / Q000379:methods; D051381:Rats; D011923:Rats, Nude; D023041:Xenograft Model Antitumor Assays / Q000379:methods